India less corrupt than Pakistan, China as per Global bribery risk matrix

Business Wire
Apex Sells Jayhawk Wind, with Facebook PPA, to WEC Energy Group and Invenergy
Apex Clean Energy sold Jayhawk Wind with Facebook power purchase agreement—Apex's fourth PPA with the tech company—to WEC Energy Group and Invenergy.
a few seconds ago
Business Wire
Schrödinger to Present at the H.C. Wainwright Global Life Sciences Conference
Schrödinger today announced that management will provide a corporate overview during the H.C. Wainwright Global Life Sciences Conference.
a few seconds ago
Business Wire
VBI Vaccines to Present at the Raymond James 42nd Annual Institutional Investors Conference
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that Jeff Baxter, President and Chief Executive Officer, and David E. Anderson, Ph.D., Chief Scientific Officer, will participate in an analyst-led fireside chat at the Raymond James 42nd Annual Institutional Investors Conference on Tuesday, March 2, 2021, at 4:40 PM ET.
2 minutes ago
Business Wire
Hudson Nonstop, Powered By Amazon’s Just Walk Out Technology, Takes Flight At Dallas Love Field Airport
Hudson, a travel experience leader with more than 1,000 stores in airports, commuter hubs, landmarks and tourist destinations across North America, today unveiled its first-ever Hudson Nonstop store using Amazon’s Just Walk Out technology at Dallas Love Field Airport (DAL), revolutionizing the in-store shopping experience for travelers with safety, speed, and convenience at the forefront.
2 minutes ago
Business Wire
1E Transitions to ServiceNow’s Elite Partner Program
1E transitions to the ServiceNow Elite Partner Program segment for support of ServiceNow customers with deeply integrated endpoint automation.
2 minutes ago
GlobeNewswire
Selecta Biosciences to Participate in the H.C. Wainwright Global Life Sciences Conference
WATERTOWN, Mass., March 01, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that Selecta’s Chief Executive Officer, Carsten Brunn, Ph.D., and Chief Financial Officer, Brad Dahms, will participate in the virtual H.C. Wainwright Global Life Sciences Conference to be held March 9-10, 2021. The presentation will be available on-demand through the H.C. Wainwright conference portal, starting at 7 a.m. EST on Tuesday, March 9, 2021. A webcast will also be available in the Investors & Media section of the company’s website at www.selectabio.com. About Selecta Biosciences, Inc.Selecta Biosciences Inc. (NASDAQ: SELB) is leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses. With a proven ability to induce tolerance to highly immunogenic proteins, ImmTOR has the potential to amplify the efficacy of biologic therapies, including redosing of life-saving gene therapies, as well as restore the body’s natural self-tolerance in autoimmune diseases. The company’s first program aimed at addressing immunogenicity to AAV gene therapies is expected to enter clinical trials in early 2021 in partnership with AskBio for the treatment of methylmalonic acidemia (MMA), a rare metabolic disorder. A wholly-owned program focused on addressing IgA nephropathy driven by ImmTOR and a therapeutic enzyme is also in development among additional product candidates. Selecta recently licensed its Phase 3 clinical product candidate, SEL-212, in chronic refractory gout to Sobi. For more information, please visit www.selectabio.com. For Investors:Bruce MackleLifeSci Advisors, LLC+1-929-469-3859bmackle@lifesciadvisors.com For Media: Meredith Sosulski, Ph.D.LifeSci Communications, LLC+1-929-469-3851msosulski@lifescicomms.com
2 minutes ago
GlobeNewswire
Applied Molecular Transport Expands Clinical Pipeline and Announces First Subject Dosed in Phase 1a Trial of Oral AMT-126
Company expands pipeline with second clinical program, AMT-126, an oral IL-22 fusion biologic therapy for diseases associated with intestinal epithelial barrier defects IL-22 deficiency implicated in broad range of gastrointestinal-focused and peripheral diseases ranging from ulcerative colitis to multiple rheumatologic disorders Complete oral AMT-126 Phase 1a/b data in healthy volunteers and patients anticipated in 2022 Company on track to announce oral AMT-101 top-line data readouts from the four Phase 2 trials from its comprehensive clinical program beginning in the second half of 2021 SOUTH SAN FRANCISCO, Calif., March 01, 2021 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced the first in human dosing in its Phase 1a clinical trial of oral AMT-126. The randomized, placebo controlled, single ascending dose Phase 1a trial is evaluating the safety, tolerability, pharmacodynamics and pharmacokinetics of AMT-126, a novel, gastrointestinal (GI)-selective oral fusion of human interleukin-22 (hIL-22), in up to 50 healthy volunteers. “We have rapidly advanced into the clinic our second novel program leveraging our platform technology to create a pipeline of transformational oral biologic therapeutics with unique and differentiated profiles,” said Tahir Mahmood, Ph.D., chief executive officer and co-founder of AMT. “Based on our important preclinical findings to date and similar to our lead program, AMT-101, an oral IL-10 fusion biologic therapy, AMT-126 has the potential to be another pipeline in a product for the company targeting both GI-focused and peripheral diseases. Advancing AMT-126 into the clinic further validates AMT’s broad oral biologics technology platform and we look forward to generating additional pipeline products to address diseases with significant unmet needs. In addition to this recent progress with AMT-126, the company remains on track to announce oral AMT-101 top-line data readouts from the four Phase 2 trials from its comprehensive clinical program beginning in the second half of this year.” “Following this Phase 1a single ascending dose trial, we intend to advance AMT-126 into a Phase 1b trial in patients who have gastrointestinal barrier dysfunction and expect the full Phase 1 development plan to resemble our AMT-101 approach,” said Bittoo Kanwar, M.D., chief medical officer of AMT. “Given the well-established role of IL-22 to promote a healthy epithelial barrier and regulate inflammation, we see enormous potential for AMT-126 to address both gastrointestinal disease and peripheral disease secondary to GI dysfunction. Because AMT-126 is designed to be gut selective, we believe it may have an improved safety profile when compared to systemically administered IL-22.” About AMT-126 AMT-126 is a novel GI-selective, oral fusion of hIL-22 and AMT’s proprietary carrier molecule currently in development for diseases related to intestinal epithelial (IE) barrier defects. IL-22 is a cytokine that repairs structural and functional defects of the IE barrier and induces microbial defense. AMT-126 is designed to act locally on the epithelial cells of the intestinal tissue, thereby repairing the IE barrier and supporting mucosal healing. About AMT-101 AMT-101 is a novel GI-selective, oral fusion of hIL-10 and AMT’s proprietary carrier molecule, which is currently being developed in four Phase 2 clinical trials in inflammatory bowel diseases and rheumatoid arthritis. AMT-101 is designed to cross the intestinal epithelium barrier with limited entry into the bloodstream, thereby focusing hIL-10 at the primary site of inflammation for UC and, potentially avoiding the side effects observed with systemic administration. By design, AMT-101 is actively transported through the IE barrier into the GI tissue, the primary site of inflammation in UC. About Applied Molecular Transport Inc. Applied Molecular Transport Inc. is a clinical-stage biopharmaceutical company leveraging its proprietary technology platform to design and develop a pipeline of novel oral biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. AMT’s proprietary technology platform allows it to exploit existing natural cellular trafficking pathways to facilitate the active transport of diverse therapeutic modalities across the intestinal epithelium (IE) barrier. Active transport is an efficient mechanism that uses the cell’s own machinery to transport materials across the IE barrier. AMT believes that its ability to exploit this mechanism is a key differentiator of its approach. AMT is developing additional oral biologic product candidates in patient-friendly oral forms that are designed to either target local gastrointestinal tissue or enter systemic circulation to precisely address the relevant biology of a disease. AMT’s headquarters, internal GMP manufacturing and lab facilities are located in South San Francisco, CA. For additional information on AMT, please visit www.appliedmt.com. Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or AMT’s future plans, strategy and performance. Such statements include, but are not limited to, the potential of, and expectations regarding the potential of, potential benefits of, and expectations regarding AMT’s technology platform and AMT-101 and AMT-126, statements regarding AMT’s Phase 2 clinical trials for AMT-101 including the timing of such trials, expectations relating to data readouts from the Phase 2 clinical trials, AMT’s ability to leverage its technology to expand its pipeline and the timing of receipt of AMT-126 Phase 1a/b data. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially, including those more fully described under the section entitled “Risk Factors” in documents the company files from time to time with the Securities and Exchange Commission. These forward-looking statements are made as of the date of this press release, and AMT assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investor Relations Contact:Andrew ChangHead, Investor Relations & Corporate Communicationsachang@appliedmt.com Media Contacts:Alexandra SantosWheelhouse Life Science Advisorsasantos@wheelhouselsa.com Aljanae ReynoldsWheelhouse Life Science Advisorsareynolds@wheelhouselsa.com
2 minutes ago
GlobeNewswire
Brunswick Exploration Options Nickel Property in Quebec
MONTREAL, March 01, 2021 (GLOBE NEWSWIRE) -- Brunswick Exploration Inc. (“BRW” or the “Company”) is pleased to announce that is has signed option and purchase agreements from a private company and prospectors to acquire a 100% interest in the Lac Édouard Nickel Project (“Lac Édouard” or the “Property”), located 40 km northeast of the town of La Tuque, Quebec, and 125 km northwest of Quebec City. Access to the site is by paved road and includes a significant nickel-copper mineralized mafic-ultramafic body that was last drilled in 1971 and which offers excellent exploration potential. Mr. Killian Charles, President of BRW, commented: “We are very excited to announce this new greenfield nickel-copper project for the Company, especially in light of rising nickel and copper prices and projected high demand for nickel in a decarbonizing economy. The Lac Édouard system has not seen drilling since 1971, contains high-grade nickel sulfide mineralization, and fits very nicely with a Voisey’s Bay deposit model. Importantly, the feeder to the mineralized system has never been identified, and the system is open down-dip to the north and to the east. Furthermore, the historical mineralization was never assayed for platinum, palladium or cobalt. Potential extensions and feeders will be drill-tested as soon as permits can be obtained within the next 2 to 3 months." Lac Édouard Property Overview The total Property package comprises 33 claims with a total surface area of 1838.5 hectares (18.4 square kilometres), is paved-road accessible and located within the Portneuf geological domain (Grenville Geological Province). Near-surface nickel mineralization was discovered in 1966 and the Property was drilled between 1967 and 1971 (total of 54 shallow holes), defining a small nickel deposit, which was further investigated with a small open pit extraction in 1972-1973. All drill holes were shallow (maximum vertical depth of 150 metres), and the best historical drill intersections (MERQ assessment files) include: DDHLENGTH (m)Ni (%)Cu (%)B26.42.000.51B413.12.310.56B314.31.330.52B66-70727.31.340.55 Exploration Targets Historical records indicate no assays were done for cobalt nor platinum-palladium, and that all drilling was limited to a small area measuring 330 x 300 metres. 3D geological modelling indicates the main intrusive system is open to the north (down-dip), open to the east, and a 2007 airborne geophysical survey indicates the presence of EM conductors stretching to the east from the known mineralized body.Quebec government stream geochemical surveys indicate anomalies of up to 400 ppm Ni in sediments, located 1,100 metres north of the deposit. In addition, other ultramafic intrusive bodies on the Property have never been drilled. The Property is considered highly prospective as the host layered intrusions include websterite, minor harzburgite and norite, as well as high-tenor mineralization (3-4% Ni in 100% sulfides). A Voisey’s Bay type metallogenic model applies well to this property, in that late-tectonic fertile mafic-ultramafic bodies intrude older sulfide-bearing gneiss/migmatite terranes and have presumably been fed by deeper mineralized magma conduits (chonoliths). Option and Purchase Terms (All dollar figures in Canadian dollars) Brunswick optioned 25 claims representing 1,374.5 hectares from Les Ressources Tectonic Inc. The option allows BRW to acquire a 100% interest in the Property over a three-year period for a total cash consideration of $170,000 and exploration expenditures of $500,000 under the following terms: Upon closing of the formal agreement, Brunswick Exploration will pay $15,000 dollars;Upon the first-year anniversary of the closing, Brunswick Exploration will pay $45,000 and will have completed $100,000 in exploration;Upon the second-year anniversary of the closing, Brunswick Exploration will pay $50,000 and will have completed and additional $150,000 in exploration;Upon the third-year anniversary of the closing, Brunswick Exploration will pay $60,000 and will have completed and additional $250,000 in exploration; The schedule can be accelerated at BRW’s discretion. BRW has also granted a two percent (2%) NSR on the claims covered by the option agreement. The first half (1%) of the NSR may be repurchased upon payment of $1,500,000 from BRW to the optionor. BRW retains a first right of purchase of the second half of the NSR. Additionally, the Company has purchased a 100% interest in 8 peripheral claims (464 hectares) to the optioned property from local prospectors for a cash consideration of $14,400. BRW has also granted a two percent (2%) NSR on the purchased claim. The first half (1%) of the NSR may be repurchased upon payment of $1,000,000 from BRW to the vendors. The second half may be purchased for $2,000,000. If BRW elects to complete both payments, it will have repurchased the entirety of the royalty on the eight purchased claims. Corporate Update Brunswick Exploration would like to announce a corporate website is now available at www.brwexplo.ca. Furthermore, following a request by the TSXV, the Company confirms that the number of flow-through shares issued on December 18, 2020 pursuant to the Company's private placement was 9,082,344 flow-through shares at a price of $0.22 per flow-through share for gross proceeds of $1,998,116 instead of 9,122,344 flow-through shares for gross proceeds of $2,006,916 as announced in the Company's press release dated December 21, 2020. Qualified Person The scientific and technical information contained in this press release has been reviewed and approved by Mr. Robert Wares, P. Geo, CEO of Brunswick Exploration. About Brunswick Exploration The Company, formerly Komet Resources Inc., is part of the Osisko Group of companies and is a Montreal-based mineral exploration venture listed on the TSX-V under symbol BRW. The Company has sold its former African assets and is now focused on exploration and development of gold and base metal properties in Eastern Canada. Current projects include gold-polymetallic vein systems in Southern New Brunswick (Fundy Gold Project), base metals VMS in the Bathurst Camp in northern New Brunswick and in the Chibougamau region of Quebec (Waconichi), and the new Lac Édouard nickel-copper project in Québec. Investor Relations/information Mr. Killian Charles, President (kcharles@BRWexplo.com). Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release Cautionary Statement on Forward-Looking Information This news release contains "forward-looking information" within the meaning of applicable Canadian securities legislation based on expectations, estimates and projections as at the date of this news release. Forward-looking information involves risks, uncertainties and other factors that could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information. Factors that could cause actual results to differ materially from such forward-looking information include, but are not limited to, delays in obtaining or failures to obtain required governmental, environmental or other project approvals; uncertainties relating to the availability and costs of financing needed in the future; changes in equity markets; inflation; fluctuations in commodity prices; delays in the development of projects; the other risks involved in the mineral exploration and development industry; and those risks set out in the Corporation’s public documents filed on SEDAR at www.sedar.com. Although the Corporation believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. The Corporation disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.
2 minutes ago
Business Wire
Boehringer Ingelheim and Gubra Join Forces to Identify and Validate Innovative Peptides for the Treatment of Obesity
Boehringer Ingelheim and Gubra today announced a new research and licensing agreement focused on the identification and validation of targets and innovative peptide compounds for the treatment of obesity. This new collaboration builds on the positive experience from previous partnerships with Gubra and combines Gubra’s proprietary streaMLine platform and expertise in obesity and peptide chemistry with Boehringer Ingelheim’s expertise in lead optimization and clinical development. The companies share the goal of providing new obesity therapies with increased tolerability that support greater weight loss than current therapy options.
2 minutes ago
GlobeNewswire
Caelum Biosciences Announces Collaborations with the Amyloidosis Advocacy Community and Support of Amyloidosis Awareness Month
BORDENTOWN, N.J., March 01, 2021 (GLOBE NEWSWIRE) -- Caelum Biosciences, Inc. (“Caelum”), a clinical-stage biotechnology company developing treatments for rare and life-threatening diseases, today announced its collaboration with and support of the amyloidosis advocacy community as Amyloidosis Awareness Month begins. The campaign was created to spread awareness about this rare disease and its symptoms to help prompt earlier diagnosis for patients. In honor of the month and Rare Disease Day, Caelum has made several commitments to the amyloidosis community that seek to raise awareness, educate, support and empower patients diagnosed with amyloidosis and their families. Caelum has provided an unrestricted donation to the Amyloidosis Support Groups; provided support for the Amyloidosis Foundation patient travel grant program, which provides travel expense assistance to medical appointments for newly diagnosed patients and their caregivers; and made a donation to the Cardiac Amyloidosis in Athletes Foundation. In addition, throughout the month of March, Caelum will be recognizing the “Light the Night for Amyloidosis” campaign that drives awareness about amyloidosis by encouraging participants to light up their entryways with red bulbs during the month. Amyloidosis represents several different types of diseases where an abnormal protein, amyloid, is produced. Amyloid protein fibers can cause significant health problems as they attach and deposit into organs, tissues, nerves and other places in the body. The most common type, AL amyloidosis, is a rare systemic disorder caused by an abnormality of plasma cells in the bone marrow. Symptoms of AL amyloidosis vary by patient, depending on which organs are affected by the amyloid deposits, but can include impairment of many organs, nerves and soft tissues, among them the kidneys, heart, digestive system and nervous system. Chronic kidney disease, arrhythmia, nausea, diarrhea, constipation, peripheral neuropathy and autonomic neuropathy are potential symptoms of the disease. “Caelum is proud to work with the amyloidosis community to increase awareness of this devastating set of diseases,” said Michael Spector, President and Chief Executive Officer of Caelum. “We are grateful for the patients who participate in our clinical trials and their families, as it is with their ongoing commitment that we hope to improve the current standard of care by advancing a treatment that directly addresses the organ dysfunction caused by amyloid deposition.” Caelum’s Cardiac Amyloid Reaching for Extended Survival (CARES) clinical program is evaluating CAEL-101, a first-in-class monoclonal antibody designed to improve organ function by reducing or eliminating amyloid deposits in the tissues and organs of patients with AL amyloidosis. Enrollment is ongoing in two parallel Phase 3 studies – one in patients with Mayo stage IIIa disease and one in patients with Mayo stage IIIb disease (ClinicalTrials.gov Identifier: NCT04512235 and NCT04504825), both of which provide a travel stipend for participating patients. The company also has a Phase 2 clinical study that is evaluating the safety and tolerability of CAEL-101 in patients with AL amyloidosis (ClinicalTrials.gov Identifier: NCT04304144). About CAEL-101CAEL-101 is a first-in-class monoclonal antibody (mAb) designed to improve organ function by reducing or eliminating amyloid deposits in the tissues and organs of patients with AL amyloidosis. The antibody is designed to bind to misfolded light chain protein and amyloid and shows binding to both kappa and lambda subtypes. In a Phase 1a/1b study, CAEL-101 demonstrated improved organ function, including cardiac and renal function, in 27 patients with relapsed and refractory AL amyloidosis who had previously not had an organ response to standard of care therapy. CAEL-101 has received Orphan Drug Designation from both the U.S. Food and Drug Administration and European Medicine Agency as a therapy for patients with AL amyloidosis. About AL AmyloidosisAL amyloidosis is a rare systemic disorder caused by an abnormality of plasma cells in the bone marrow. Misfolded immunoglobulin light chains produced by plasma cells aggregate and form fibrils that deposit in tissues and organs. This deposition can cause widespread and progressive organ damage and high mortality rates, with death most frequently occurring as a result of cardiac failure. Current standard of care includes plasma cell directed chemotherapy and autologous stem cell transplant, but these therapies do not address the organ dysfunction caused by amyloid deposition, and up to 80 percent of patients are ineligible for transplant. AL amyloidosis is a rare disease but is the most common form of amyloidosis. There are approximately 22,000 patients across the United States, France, Germany, Italy, Spain and the United Kingdom. AL amyloidosis has a one-year mortality rate of 47 percent, 76 percent of which is caused by cardiac amyloidosis. About Caelum BiosciencesCaelum Biosciences, Inc. (“Caelum”) is a clinical-stage biotechnology company developing treatments for rare and life-threatening diseases. Caelum’s lead asset, CAEL-101, is a novel antibody for the treatment of patients with amyloid light chain (“AL”) amyloidosis. In 2019, Caelum entered a collaboration agreement with Alexion Pharmaceuticals, Inc. (“Alexion”) under which Alexion acquired a minority equity interest in Caelum and an exclusive option to acquire the remaining equity in the company. Caelum was founded by Fortress Biotech, Inc. (NASDAQ: FBIO). For more information, visit www.caelumbio.com.Company Contacts:Michael Spector, President & Chief Executive Officermspector@caelumbio.com Jaclyn Jaffe and William BegienInvestor Relations(781) 652-4500info@caelumbio.com Media Relations Contact:Tony Plohoros6 Degrees(908) 591-2839tplohoros@6degreespr.com
2 minutes ago
Business Wire
Siemens Energy and Intermountain Power Agency Drive Transition to Sustainable Energy Through Study of Hydrogen Energy Storage at a Utility-Scale Power Plant in Utah
Siemens Energy announced today that it has teamed up with Intermountain Power Agency to perform a conceptual design study on integrating a hydrogen energy storage system into an advanced class combined cycle power plant. The project has been awarded a $200,000 grant from the U.S. Department of Energy, one of four funding awards received by Siemens Energy in late 2020 to advance hydrogen applications in the U.S. power generation sector.
2 minutes ago
Business Wire
Tenaya Therapeutics Secures $106 Million in Series C Funding to Accelerate Pipeline of Potentially Curative Therapies for Heart Disease
Tenaya Therapeutics, a company developing curative therapies for heart disease, today announced that it has secured $106 million in Series C funding.
2 minutes ago
Business Wire
WP Engine International Growth Led by Agency Focus
WP Engine, the world’s most trusted WordPress technology company, saw impressive growth in its International Business Unit in 2020, which now numbers more than 30,000 international customers, led by a growing list of referring agency customers who account for more than half of the revenue across EMEA and Australia. WP Engine’s international operations added an office in Krakow, Poland to its growing list of international offices that includes London; Limerick, Ireland and Brisbane, Australia. The company also grew its employee base across those offices while earning multiple accolades as a great place to work.
2 minutes ago
Business Wire
Robert Mocerino Joins White Oak to Lead Staffing and Government Contracting Finance Originations
White Oak Commercial Finance ("White Oak"), an affiliate of White Oak Global Advisors, is pleased to welcome Robert Mocerino as Senior Vice President, Managing Director of Staffing and Government Originations. He will be based in New York with national coverage responsibilities reporting to Bob Grbic, President & CEO of White Oak Commercial Finance.
2 minutes ago
Business Wire
Altice USA to Acquire Morris Broadband
Altice USA (NYSE: ATUS) today announced it has entered into a definitive agreement to acquire the assets of Morris Broadband, LLC ("Morris Broadband"). The transaction will expand Altice USA’s footprint in North Carolina, where it already has a presence with its Suddenlink business, and implies an enterprise value of $310 million total for the Morris Broadband business on a debt-free and cash-free basis. Following this acquisition, North Carolina will represent the sixth largest state for Altice USA out of its 21 states of operations in terms of number of residential customers, demonstrating the Company’s commitment to invest heavily in the region with additional resources and network investments.
2 minutes ago
Business Wire
CIIG Merger Corp. Announces Registration Statement in Connection With Its Proposed Business Combination With Arrival S.à r.l. Has Been Declared Effective and Sets the Record Date and Meeting Date for the Special Meeting of Stockholders
CIIG Merger Corp. (NASDAQ: CIIC) ("CIIG") today announced that the U.S. Securities and Exchange Commission ("SEC") has declared effective the registration statement on Form F-4 of Arrival Group (File No. 333-251339) (as amended, the "Registration Statement"), which includes a definitive proxy statement/prospectus in connection with CIIG’s special meeting of stockholders (the "Special Meeting") to consider the previously announced proposed business combination (the "Business Combination") with Arrival S.à r.l. ("Arrival"). Additionally, CIIG today announced that it has set a record date of February 16, 2021 (the "Record Date") and a meeting date of March 19, 2021 for its Special Meeting.
2 minutes ago
Business Wire
Foresight: Eye-Net Successfully Completes Trial with a Top Global Vehicle Manufacturer
Foresight: Eye-Net Successfully Completes Trial with a Top Global Vehicle Manufacturer
2 minutes ago
Business Wire
Twist Bioscience to Highlight Genotyping by Sequencing and Methylation Solution During AGBT
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced several events at the virtual 2021 Advances in Genome Biology and Technology (AGBT) meeting to be held March 1-3, 2021.
2 minutes ago
Business Wire
TransAct Secures BOHA!® Solutions Order with Regional Convenience Store Operator
TransAct® Technologies Incorporated (Nasdaq: TACT) ("TransAct" or "the Company"), a global leader in software-driven technology and printing solutions for high-growth markets, today announced that it has secured a new BOHA! ® agreement with a regional convenience store operator. The company expects to deploy the BOHA! system to over 40 locations in support of their privately-branded and third party fresh food offerings.
2 minutes ago
Business Wire
Jefferies' Clients, Employees and Shareholders "Do Good" by Donating $8,300,000 to 129 Charities
Jefferies announced today a total donation of approximately $8.3 million that will result in 129 charities each receiving $65,000. Jefferies’ firmwide global charity trading day effort will send much needed funds to accredited charities focused on advancing diversity and inclusion, supporting COVID-19 relief efforts, enabling Texas Relief, improving sustainability and the environment and other worthy causes.
2 minutes ago

Rank	Country
1	Denmark
2	Norway
3	Finland
4	Sweden
5	New Zealand
6	Netherlands
7	Switzerland
8	Germany
9	United Kingdom
10	Iceland
11	Canada
12	Australia
13	Estonia
14	Belgium
15	Singapore
16	Ireland
17	Austria
18	Luxembourg
19	Taiwan
20	Hong Kong
21	Japan
22	South Korea
23	United States
24	France
25	Portugal
26	Spain
27	Lithuania
28	Georgia
29	Uruguay
30	Andorra
31	Slovenia
32	Cyprus
33	Chile
34	Latvia
35	Israel
36	Italy
37	Costa Rica
38	Czech Republic
39	Liechtenstein
40	United Arab Emirates
41	Poland
42	Puerto Rico
43	Armenia
44	Greece
45	Malta
46	Mauritius
47	Jamaica
48	Bhutan
49	Barbados
50	St.VincentandtheGrenadines
51	Malaysia
52	Slovak Republic
53	Botswana
54	St. Lucia
55	Tunisia
56	San Marino
57	Croatia
58	Namibia
59	Antigua and 41 Barbuda
60	St. Kitts and Nevis
61	South Africa
62	Trinidad and Tobago
63	Cape Verde
64	BruneiDarussalam
65	Seychelles
66	Panama
67	Senegal
68	Grenada
69	Bulgaria
70	Dominica
71	Marshall Islands
72	Argentina
73	Romania
74	Indonesia
75	Ghana
76	Peru
77	India
78	Jordan
79	North Macedonia
80	Colombia
81	Montenegro
82	Bahamas
83	Kuwait
84	Kosova
85	Maldives
86	Rwanda
87	Sri Lanka
88	Thailand
89	Fiji
90	Brazil
91	Micronesia
92	Sao Tome and Principe
93	Vanuatu
94	Oman
95	Morocco
96	Mongolia
97	Burkina Faso
98	Ukraine
99	Mexico
100	Samoa
101	Palau
102	Benin
103	Dominican Republic
104	Serbia
105	Lesotho
106	Moldova
107	Nepal
108	Saudi Arabia
109	El Salvador
110	Hungary
111	Qatar
112	Tonga
113	Phillipines
114	Turkey
115	Albania
116	Suriname
117	Gambia
118	Eucador
119	Guyana
120	Paraguay
121	Soloman Islands
122	East Timor
123	Kazakhstan
124	Kenya
125	Belarus
126	China
127	Russian Federation
128	Tanzania
129	Niger
130	Kyrgyz Republic
131	Guatemala
132	Bosnia and Herzegovina
133	Bahrain
134	Malawi
135	Mynamar
136	Azerbaijan
137	Papua New Guinea
138	Togo
139	Ivory Coast
140	Vietnam
141	Uganda
142	Mozambique
143	Belize
144	Lebanon
145	Kiribati
146	Eswatini
147	Zambia
148	Honduras
149	Sierra Leone
150	Ubekistan
151	Bolivia
152	Guinea
153	Pakistan
154	Mali
155	Nigeria
156	Iraq
157	Madagascar
158	Zimbabwe
159	Liberia
160	Egypt
161	Djibouti
162	Guinea-Bissau
163	Ethiopia
164	Algeria
165	Comoros
166	Bangladesh
167	Sudan
168	Gabon
169	Cameroon
170	Cuba
171	Afghanistan
172	Nicaragua
173	Libya
174	Tajikistan
175	Mauritania
176	Angola
177	Iran
178	Haiti
179	Central African Republic
180	Dem. Rep. of the Congo
181	Republic of the 72 Congo (Brazzaville)
182	Laos
183	Burundi
184	Chad
185	Syria
186	Cambodia
187	Somalia
188	EquatorialGuinea
189	Yemen
190	Eritrea
191	Venezuela
192	South Sudan
193	Turkmenistan
194	North Korea

BSE SENSEX

Nifty 50

Dow

Nasdaq

BTC-INR

CMC Crypto 200

Hang Seng

Nikkei

EUR/INR

GBP/INR

AED/INR

INR/JPY

SGD/INR

India less corrupt than Pakistan, China as per Global bribery risk matrix

Latest stories

Apex Sells Jayhawk Wind, with Facebook PPA, to WEC Energy Group and Invenergy

Schrödinger to Present at the H.C. Wainwright Global Life Sciences Conference

VBI Vaccines to Present at the Raymond James 42nd Annual Institutional Investors Conference

Hudson Nonstop, Powered By Amazon’s Just Walk Out Technology, Takes Flight At Dallas Love Field Airport

1E Transitions to ServiceNow’s Elite Partner Program

Selecta Biosciences to Participate in the H.C. Wainwright Global Life Sciences Conference

Applied Molecular Transport Expands Clinical Pipeline and Announces First Subject Dosed in Phase 1a Trial of Oral AMT-126

Brunswick Exploration Options Nickel Property in Quebec

Boehringer Ingelheim and Gubra Join Forces to Identify and Validate Innovative Peptides for the Treatment of Obesity

Caelum Biosciences Announces Collaborations with the Amyloidosis Advocacy Community and Support of Amyloidosis Awareness Month

Siemens Energy and Intermountain Power Agency Drive Transition to Sustainable Energy Through Study of Hydrogen Energy Storage at a Utility-Scale Power Plant in Utah

Tenaya Therapeutics Secures $106 Million in Series C Funding to Accelerate Pipeline of Potentially Curative Therapies for Heart Disease

WP Engine International Growth Led by Agency Focus

Robert Mocerino Joins White Oak to Lead Staffing and Government Contracting Finance Originations

Altice USA to Acquire Morris Broadband

CIIG Merger Corp. Announces Registration Statement in Connection With Its Proposed Business Combination With Arrival S.à r.l. Has Been Declared Effective and Sets the Record Date and Meeting Date for the Special Meeting of Stockholders

Foresight: Eye-Net Successfully Completes Trial with a Top Global Vehicle Manufacturer

Twist Bioscience to Highlight Genotyping by Sequencing and Methylation Solution During AGBT

TransAct Secures BOHA!® Solutions Order with Regional Convenience Store Operator

Jefferies' Clients, Employees and Shareholders "Do Good" by Donating $8,300,000 to 129 Charities